Angel Matthew 4

4 · Tempest Therapeutics, Inc. · Filed Jun 23, 2026

AI-generated summary of this filing

Updated Jun 23, 2026

Tempest (TPST) 10% Owner Angel Matthew Buys 231,482 Shares

What Happened

Angel Matthew, the majority stockholder and Chairman of Factor Biosciences (and reported as a 10% owner), is reporting a purchase: on March 24, 2026 Factor acquired 231,482 shares of Tempest Therapeutics common stock. The reported cash consideration for the shares was $2.16 per combined unit (share + accompanying warrant), totaling $500,001. In addition, Factor received warrants to purchase 462,964 shares (reported as derivative securities).

Key Details

Transaction date: 2026-03-24. Transaction code: P (purchase).
Share count purchased: 231,482 common shares for reported cash of $500,001 (effective combined price $2.16 per share + warrant).
Derivatives: warrants to purchase 462,964 shares were issued to Factor (details subject to stockholder approval per filing).
Warrant terms noted: Series A warrants become exercisable on the effective date of stockholder approval and run for five years; Series B warrants (also subject to approval) would run for 24 months from approval (per footnotes).
Reporting relationship: the filing states the Reporting Person (Angel Matthew) is the majority stockholder and Chairman of Factor and exercises voting and investment power over the shares held by Factor.
Shares owned after transaction: not specified in the provided filing summary.
Timeliness: filing was reported late due to an inadvertent administrative oversight (the Form 4 indicates a late filing).

Context

This filing reports a purchase by an affiliated investor entity (Factor) controlled by Angel Matthew, not a stock sale by a company executive. Purchases can be viewed by some investors as a positive/affirmative signal, but filings do not disclose motive. The warrants are derivative instruments and require company stockholder approval before becoming exercisable; the timing and ultimate value will depend on that approval and future stock performance.

Form 4

Period: 2026-03-24

DirectorCEO and President10% Owner

Transactions

Purchase
Common Stock
[F2][F1][F3]
2026-03-24$2.16/sh+231,482$500,001→ 231,482 total(indirect: By Factor Bioscience Inc.)
Purchase
Series A Warrant (right to buy)
[F1][F2][F4][F3]
2026-03-24+231,482→ 231,482 total(indirect: By Factor Bioscience Inc.)
Exercise: $2.16→ Common Stock (231,482 underlying)
Purchase
Series B Warrant (right to buy)
[F1][F2][F5][F3]
2026-03-24+231,482→ 231,482 total(indirect: By Factor Bioscience Inc.)
Exercise: $2.16→ Common Stock (231,482 underlying)

Footnotes (5)

[F1]On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.
[F2]The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.
[F3]The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.
[F4]The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval.
[F5]The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval.

Signature

/s/ Matthew Angel|2026-06-23

1 file